0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Clinical and Research Reports   |    
Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series
Domenico De Berardis, M.D., Ph.D.; Michele Fornaro, M.D.; Nicola Serroni, M.D.; Luigi Olivieri, M.D.; Stefano Marini, M.D.; Francesco Saverio Moschetta, M.D.; Venkataramanujam Srinivasan, Ph.D.; Maurizio Assetta, M.D.; Alessandro Valchera, M.D.; Anatolia Salone, M.D., Ph.D.; Giovanni Martinotti, M.D., Ph.D.; Marco Onofrj, M.D.; Massimo Di Giannantonio, M.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2013;25:343-345. doi:10.1176/appi.neuropsych.12110286
View Author and Article Information

All authors have equally contributed to the present case series.

Conflicts of Interest and Source of Funding: The authors have no conflict of interest to declare.

From NHS, Dept. of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini,” Teramo, Italy (DDB, NS, LO, SM, FSM), Dept. of Neuroscience and Imaging, University “G. D’Annunzio,” Chieti, Italy (DDB, SM, AS, GM, MDG), Dept. of “Scienze della Formazione,” University of Catania, Italy (MF), Sri Sathya Sai Medical Educational and Research Foundation, Medical Sciences Research Study Center, Prasanthi Nilayam, Tamilnadu, India (VS), U.O.C. Neurology, Hospital “G. Mazzini,” ASL 4 Teramo, Italy (MA), Villa San Giuseppe Hospital, Hermanas Hospitalarias, Ascoli Piceno, Italy (AV), Dept. of Neuroscience and Imaging, Neurology, University “G. D’Annunzio,” Chieti, Italy (MO).

Send correspondence to Dr. De Berardis; e-mail: dodebera@aliceposta.it

Copyright © 2013 by the American Psychiatric Association

Received November 22, 2012; Revised March 21, 2013; Accepted April 08, 2013.

Abstract

Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in the course of Parkinson’s disease (PD), and therefore, most PD patients receive antidepressant drugs. Agomelatine is a recently introduced antidepressant drug acting as an MT1/MT2 melatonergic receptor agonist and 5HT2C/5HT2B serotonergic antagonist. The aim of this case series was to evaluate the role of agomelatine in the treatment of MDD associated with PD.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

+

References

Veazey  C;  Aki  SO;  Cook  KF  et al:  Prevalence and treatment of depression in Parkinson’s disease.  J Neuropsychiatry Clin Neurosci 2005; 17:310–323
[CrossRef] | [PubMed]
 
Weintraub  D;  Taraborelli  D;  Morales  KH  et al:  Escitalopram for major depression in Parkinson’s disease: an open-label, flexible-dosage study.  J Neuropsychiatry Clin Neurosci 2006; 18:377–383
[CrossRef] | [PubMed]
 
Lauterbach  EC;  Victoroff  J;  Coburn  KL  et al:  Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.  J Neuropsychiatry Clin Neurosci 2010; 22:8–18
[CrossRef] | [PubMed]
 
Fornaro  M;  Prestia  D;  Colicchio  S  et al:  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.  Curr Neuropharmacol 2010; 8:287–304
[CrossRef] | [PubMed]
 
De Berardis  D;  Di Iorio  G;  Acciavatti  T  et al:  The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.  CNS Neurol Disord Drug Targets 2011; 10:119–132
[CrossRef] | [PubMed]
 
Martinotti  G;  Sepede  G;  Gambi  F  et al:  Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.  J Clin Psychopharmacol 2012; 32:487–491
[CrossRef] | [PubMed]
 
Srinivasan  V;  Zakaria  R;  Othman  Z  et al:  Agomelatine in depressive disorders: its novel mechanisms of action.  J Neuropsychiatry Clin Neurosci 2012; 24:290–308
[CrossRef] | [PubMed]
 
Members of the UPDRS Development Committee:  Unified Parkinson’s Disease Rating Scale in Recent Developments in Parkinson’s Disease . Edited by Fahn  S;  Marsden  CD;  Calne  DB  et al.  Florham Park, NJ,  Macmillan Health Care Information, 1987
 
Hamilton  M:  Development of a rating scale for primary depressive illness.  Br J Soc Clin Psychol 1967; 6:278–296
[CrossRef] | [PubMed]
 
Folstein  MF;  Folstein  SE;  McHugh  PR:  “Mini-Mental State:” a practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res 1975; 12:189–198
[CrossRef] | [PubMed]
 
Snaith  RP;  Hamilton  M;  Morley  S  et al:  A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale.  Br J Psychiatry 1995; 167:99–103
[CrossRef] | [PubMed]
 
European Medicines Agency European Public Assessment Report. Valdoxan, 2012; available at http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d124; accessed Oct 28, 2012
 
Barone  P:  Treatment of depressive symptoms in Parkinson’s disease.  Eur J Neurol 2011; 18(Suppl 1):11–15
[CrossRef] | [PubMed]
 
Meerlo  P;  Sgoifo  A;  Turek  FW:  The effects of social defeat and other stressors on the expression of circadian rhythms.  Stress 2002; 5:15–22
[CrossRef] | [PubMed]
 
O’Connor  MF;  Wellisch  DK;  Stanton  AL  et al:  Diurnal cortisol in complicated and non-complicated grief: slope differences across the day.  Psychoneuroendocrinology 2012; 37:725–728
[CrossRef] | [PubMed]
 
De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant, obsessive-compulsive disorder: a case report. Case Rep Psychiatry 2012:642752
 
Debonnel  G;  Saint-André  E;  Hébert  C  et al:  Differential physiological effects of a low dose and high doses of venlafaxine in major depression.  Int J Neuropsychopharmacol 2007; 10:51–61
[CrossRef] | [PubMed]
 
Srinivasan  V;  De Berardis  D;  Shillcutt  SD  et al:  Role of melatonin in mood disorders and the antidepressant effects of agomelatine.  Expert Opin Investig Drugs 2012; 21:1503–1522
[CrossRef] | [PubMed]
 
Di Giannantonio  M;  Di Iorio  G;  Guglielmo  R  et al:  Major depressive disorder, anhedonia, and agomelatine: an open-label study.  J Biol Regul Homeost Agents 2011; 25:109–114
[PubMed]
 
Di Giannantonio  M;  Martinotti  G:  Anhedonia and major depression: the role of agomelatine.  Eur Neuropsychopharmacol 2012; 22(Suppl 3):S505–S510
[CrossRef] | [PubMed]
 
Adi  N;  Mash  DC;  Ali  Y  et al:  Melatonin MT1 and MT2 receptor expression in Parkinson’s disease.  Med Sci Monit 2010; 16:BR61–BR67
[PubMed]
 
Bruin  VM;  Bittencourt  LR;  Tufik  S:  Sleep–wake disturbances in Parkinson’s disease: current evidence regarding diagnostic and therapeutic decisions.  Eur Neurol 2012; 67:257–267
[CrossRef] | [PubMed]
 
Suzuki  K;  Miyamoto  T;  Miyamoto  M  et al:  Circadian variation of core body temperature in Parkinson disease patients with depression: a potential biological marker for depression in Parkinson disease.  Neuropsychobiology 2007; 56:172–179
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
DSM-5™ Clinical Cases > Chapter 17.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 22.  >
DSM-5™ Clinical Cases > Chapter 4.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 22.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 27.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles